RVYL:NASDAQRyvyl Inc. Analysis
Data as of 2026-04-29 - not real-time
$5.33
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Ryvyl Inc. is trading at roughly $5.33, well below its 20‑day ($5.79) and 50‑day ($5.66) simple moving averages and far beneath the 200‑day average ($8.83), indicating a prolonged downtrend. The RSI sits near 44 and the MACD histogram is negative, reinforcing a bearish technical outlook, while volume has been trending lower, suggesting waning liquidity. Fundamentally, the company reports modest revenue growth of about 4 % but is hemorrhaging cash, with operating margins of –78 % and a free cash flow deficit exceeding $11 million; debt‑to‑equity exceeds 470 % and book value per share is negative. Despite these challenges, the forward earnings estimate turns positive ($0.28), yielding a forward P/E around 19, which is well under the industry average of 37.5, hinting at potential undervaluation if the business can stabilize. Recent shareholder communications reveal a pending merger with Roundtable, with 99 % of votes already cast in favor, positioning the transaction as a pivotal catalyst for restructuring the capital base and possibly improving cash generation. However, the merger has not yet closed, leaving short‑term uncertainty high. Overall, the stock sits at the intersection of extreme market greed (fear‑greed index 89.6) and severe operational risk, making it a high‑stakes play that hinges on the successful execution of the merger and a turnaround in cash flows.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 6/10
Key Factors
- Bearish technical indicators (price below SMAs, negative MACD)
- Decreasing volume and high volatility
- Uncertainty around merger completion
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Forward earnings estimate turning positive
- Potential balance‑sheet improvement from Roundtable merger
- Low price‑to‑sales multiple relative to peers
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- High leverage and ongoing cash‑flow deficits
- Exposure to fintech regulatory environment
- Possibility of sustainable profitability if restructuring succeeds
Key Metrics & Analysis
Financial Health
Revenue Growth4.20%
Profit Margin-157.45%
P/E Ratio19.0
ROA-8.70%
Debt/Equity470.36
P/B Ratio-1.5
Op. Cash Flow$-23041000
Free Cash Flow$-11298125
Industry P/E37.5
Technical Analysis
TrendNeutral
RSI44.4
Support$4.25
Resistance$7.04
MA 20$5.79
MA 50$5.66
MA 200$8.83
MACDBearish
VolumeDecreasing
Fear & Greed Index89.59
Valuation
GradeUndervalued
TypeBlend
Risk Assessment
Beta1.75
Volatility115.79%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.